Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025
Supernus Pharmaceuticals (Nasdaq: SUPN), a biopharmaceutical company specializing in central nervous system (CNS) diseases, has scheduled its second quarter 2025 financial results announcement for August 5, 2025, after market close.
The company will host a conference call at 4:30 p.m. ET on the same day, featuring CEO Jack Khattar and CFO Tim Dec. The presentation will be available via webcast through the company's investor relations website, with a replay accessible for 60 days following the event.
Supernus Pharmaceuticals (Nasdaq: SUPN), un'azienda biofarmaceutica specializzata nelle malattie del sistema nervoso centrale (SNC), ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per il 5 agosto 2025, dopo la chiusura del mercato.
La società terrà una conference call alle 16:30 ET dello stesso giorno, con la partecipazione del CEO Jack Khattar e del CFO Tim Dec. La presentazione sarà disponibile in webcast tramite il sito web delle relazioni con gli investitori dell'azienda, con una replica accessibile per 60 giorni dopo l'evento.
Supernus Pharmaceuticals (Nasdaq: SUPN), una compañía biofarmacéutica especializada en enfermedades del sistema nervioso central (SNC), ha programado el anuncio de resultados financieros del segundo trimestre de 2025 para el 5 de agosto de 2025, después del cierre del mercado.
La empresa realizará una llamada conferencia a las 4:30 p.m. ET del mismo día, con la participación del CEO Jack Khattar y el CFO Tim Dec. La presentación estará disponible vía webcast a través del sitio web de relaciones con inversionistas de la compañía, con una repetición accesible durante 60 días después del evento.
Supernus Pharmaceuticals (나스닥: SUPN)는 중추신경계(CNS) 질환을 전문으로 하는 바이오제약 회사로, 2025년 2분기 재무실적 발표를 2025년 8월 5일 시장 마감 후로 예정했습니다.
회사는 같은 날 동부시간 오후 4시 30분에 CEO 잭 카타르(Jack Khattar)와 CFO 팀 데크(Tim Dec)가 참여하는 컨퍼런스 콜을 개최할 예정입니다. 발표 내용은 회사 투자자 관계 웹사이트를 통해 웹캐스트로 제공되며, 이벤트 후 60일간 다시보기 가능합니다.
Supernus Pharmaceuticals (Nasdaq : SUPN), une entreprise biopharmaceutique spécialisée dans les maladies du système nerveux central (SNC), a prévu l'annonce des résultats financiers du deuxième trimestre 2025 pour le 5 août 2025, après la clôture du marché.
L'entreprise organisera une conférence téléphonique à 16h30 ET le même jour, avec la participation du PDG Jack Khattar et du directeur financier Tim Dec. La présentation sera accessible en webcast via le site des relations investisseurs de la société, avec un replay disponible pendant 60 jours après l'événement.
Supernus Pharmaceuticals (Nasdaq: SUPN), ein biopharmazeutisches Unternehmen, das sich auf Erkrankungen des zentralen Nervensystems (ZNS) spezialisiert hat, hat die Veröffentlichung der Finanzergebnisse für das zweite Quartal 2025 für den 5. August 2025 nach Börsenschluss angekündigt.
Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz mit CEO Jack Khattar und CFO Tim Dec abhalten. Die Präsentation wird über einen Webcast auf der Investor-Relations-Website des Unternehmens verfügbar sein, mit einer Wiedergabe, die 60 Tage nach der Veranstaltung abrufbar ist.
- None.
- None.
ROCKVILLE, Md., July 22, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the second quarter of 2025 after the market closes on Tuesday, August 5, 2025.
Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to present the second quarter 2025 financial and business results on Tuesday, August 5, 2025 at 4:30 p.m. ET. Following management’s prepared remarks and discussion of business results, the call will be open for questions.
A live webcast will be accessible in the Events & Presentations section of the Company’s Investor Relations website at www.supernus.com/investors.
Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.
Following the live call, a replay will be available on the Company's Investor Relations website at www.supernus.com/investors. The webcast will be available on the Company’s website for 60 days following the live call.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for epilepsy, depression, and other CNS disorders.
For more information, please visit www.supernus.com.
Forward-Looking Statements
This press release includes forward-looking statements. These statements do not convey historical information but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the risk that the proposed acquisition of Sage by Supernus may not be completed; the possibility that competing offers or acquisition proposals for Sage will be made; the delay or failure of the tender offer conditions to be satisfied (or waived), including insufficient shares of Sage common stock being tendered in the tender offer; the failure (or delay) to receive the required regulatory approvals of the proposed acquisition; the possibility that prior to the completion of the transactions contemplated by the acquisition agreement, Supernus’ or the Sage’s business may experience significant disruptions due to transaction related uncertainty; the effects of disruption from the transactions of Sage’s business and the fact that the announcement and pendency of the transactions may make it more difficult to establish or maintain relationships with employees, manufactures, suppliers, vendors, business partners and distribution channels to patients; the occurrence of any event, change or other circumstance that could give rise to the termination of the acquisition agreement; the risk that stockholder litigation in connection with the proposed transaction may result in significant costs of defense, indemnification and liability; the failure of the closing conditions set forth in the acquisition agreement to be satisfied or waived; Supernus’ ability to sustain and increase its profitability; Supernus’ ability to raise sufficient capital to fully implement its corporate strategy; the implementation of Supernus’ corporate strategy; Supernus’ future financial performance and projected expenditures; Supernus’ ability to increase the number of prescriptions written for each of its products, the products of its subsidiaries, and products acquired through the acquisition of Sage; Supernus’ ability to increase its net revenue from its products, the products of its subsidiaries, and products acquired through the acquisition of Sage; Supernus’ ability to commercialize its products including Qelbree; Supernus’ ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; Supernus’ product research and development activities, including the timing and progress of Supernus’ clinical trials, and projected expenditures; Supernus’ ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize Supernus’ product candidates; Supernus’ ability to protect its intellectual property and operate its business without infringing upon the intellectual property rights of others; Supernus’ expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of Supernus’ product candidates; the accuracy of Supernus’ estimates of the size and characteristics of the markets that may be addressed by its product candidates; Supernus’ ability to increase its manufacturing capabilities for its products and product candidates; Supernus’ projected markets and growth in markets; Supernus’ product formulations and patient needs and potential funding sources; Supernus’ staffing needs; and other risk factors set forth from time to time in Supernus’ filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. Supernus undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.
CONTACTS:
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591
or
INVESTOR CONTACT:
Peter Vozzo
ICR Healthcare
(443) 213-0505
peter.vozzo@icrhealthcare.com
FAQ
When will Supernus Pharmaceuticals (SUPN) report Q2 2025 earnings?
How can I access Supernus Pharmaceuticals' Q2 2025 earnings call?
Who will present at Supernus Pharmaceuticals' Q2 2025 earnings call?
How long will Supernus Pharmaceuticals' Q2 2025 earnings call replay be available?
